Pharma BD Deal Intelligence
Eli Lilly and Company / Acrux Limited (AXIRON license)
2010 · Licensing/Option · $335M · Terminated
Announcement Sentiment
50
Neutral / mixed
Lilly entered exclusive worldwide license with Acrux for AXIRON: $50M upfront + $3M manufacturing transfer + $87M FDA marketing approval + $195M commercialization milestones, plus royalties.
Key facts
- Announced Mar 15, 2010
- Deal value $335M
- Deal type Licensing/Option
- Therapeutic area Hypogonadism (testosterone deficiency)
- Indications Hypogonadism (testosterone deficiency)
- Key assets AXIRON (testosterone topical solution)
- Mechanism Topical testosterone replacement
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals